Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
Noosa News15 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News17 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General14 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win
-
General20 hours agoOne person dead after house fire in Melbourne’s south-east